Methylation of RBM39 reverses the inhibitory of Indisulam on NSCLC.

(A) A549 and H460 cells transfected with empty vector, RBM39, or R92K, respectively, were treated with Indisulam, and the protein levels of stem-related markers were analyzed by western blotting. (B) MTT assays were performed to test the cell growth abi...

Full description

Saved in:

Bibliographic Details
Main Author:	Tongjia Zhang (16496661) (author)
Other Authors:	Shujie Wang (750318) (author), Yue Zhou (71752) (author), Zitao Jiao (21485389) (author), Kejia Lu (7538975) (author), Xinyi Liu (186154) (author), Hui Li (32376) (author), Wei Jiang (14986) (author), Xiaowei Zhang (6505) (author)
Published:	2025
Subjects:	Biophysics Biochemistry Cell Biology Genetics Molecular Biology Pharmacology Biotechnology Cancer Hematology Infectious Diseases Plant Biology Biological Sciences not elsewhere classified xenograft mouse models remains poorly understood promoting alternative splicing promotes alternative splicing potential therapeutic strategy binding protein 39 xlink "> indisulam prmt6 enhances resistance prmt6 methylates rbm39 methylation inhibits indisulam oncogenes </ p inhibiting prmt6 indisulam resistance acquired resistance ultimately leads tumor growth tumor efficacy tumor activity specific target significantly improves rbm39 ), proteasomal degradation molecular basis malignant proliferation line therapy key biomarker induced ubiquitination closely associated clinical efficacy based compound
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Methylation of RBM39 reverses the inhibitory of Indisulam on NSCLC.

Similar Items